Liza Laws, Author at Labiotech.eu

News and Trends 18 Nov 2022

Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults

Novavax, Inc., a U.S-based biotechnology company announced today (November 18) that Health Canada has granted expanded authorization for Covid-19 vaccine Nuvaxovid. The vaccine NVX-CoV2373 for active immunization to prevent the disease caused by severe acute respiratory syndrome (SARS-CoV-2) as a homologous booster in adults aged 18 and older. “Canadians now have access to our […]

November 18, 2022 - 2 minutesmins - By Liza Laws

News and Trends 18 Nov 2022

Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC

Sanofi’s treatment, Enjaymo, for hemolytic anemia in adult patients with cold agglutinin disease (CAD), has been granted marketing authorization by the European Commission (EC). Enjaymo is the first and only approved therapeutic option for the rare, serious and chronic autoimmune disease where the body mistakenly attacks healthy red blood cells and causes their rupture, known […]

November 18, 2022 - 4 minutesmins - By Liza Laws

News and Trends 18 Nov 2022

MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma

KAHR Medical, a clinical stage biotech company that is developing a treatment for solid tumors and blood cancers has received investment from the Myeloma Investment Fund (MIF). MIF has made the investment to explore the potential of DSP107, KAHR’s leading immunotherapy drug candidate for the treatment of multiple myeloma. “We are thrilled to partner with […]

November 18, 2022 - 3 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 18 Nov 2022

NW Bio reports positive top-line results from phase 3 glioblastoma trial

Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November 17) reported that both median and long tail survival were increased in both newly diagnosed and recurrent glioblastoma. The brain tumor cancer patients were treated with DCVax-L and in its phase 3 clinical trial met both the primary and secondary […]

November 18, 2022 - 4 minutesmins - By Liza Laws

News and Trends 18 Nov 2022

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) for patients previously treated HER-2 positive advanced gastric cancer. The drug is also used for gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. Enhertu is a specifically engineered HER2-directed antibody drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca […]

November 18, 2022 - 3 minutesmins - By Liza Laws

News and Trends 17 Nov 2022

Ascletis announces IND approval for treatment of advanced solid tumors

Ascletis Pharma has announced the approval of the investigational new drug (IND) application by China National Medical Products Administration (NMPA). The approval is for an in-house developed oral PD-L1 small molecule inhibitor prodrug, ASC61, for the treatment of advanced solid tumors. The ASC61 phase 1 dose escalation study is ongoing in the U.S. IND approval […]

November 17, 2022 - 2 minutesmins - By Liza Laws

News and Trends 17 Nov 2022

Startup Cradle raises $5.4M to design protein machines and cell factories with AI

Cradle, a Dutch startup, has received €5.5 million ($5.4 million) in seed funding to further help scientists design and program proteins to produce a wide variety of everyday products including milk and meat. Cradle uses synthetic biology, adapting the genes of microorganisms such as bacteria and fungi, to create ‘cell factories’ that use programmable proteins […]

November 17, 2022 - 5 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Discovery Park celebrates 10 years and plans to double jobs over the next decade

Plans to grow and double the number of people employed at Discovery Park, the UK’s biggest science and innovation center have been announced. The team behind its success shared the news as they celebrate a decade of delivering jobs and investment in the South East. Discovery Park marked the milestone by announcing its plans for […]

November 16, 2022 - 4 minutesmins - By Liza Laws

More News! 16 Nov 2022

Mineralys has positive topline results from trial evaluating treatment of hypertension

U.S.-based Mineralys Therapeutics, Inc., announced today (November 16) topline results from its phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension. MLS-101, a highly selective investigational aldosterone synthase inhibitor, at doses of 50 mg and 100 mg once daily, met its primary endpoint with statistically significant and clinically meaningful reduction in systolic blood […]

November 16, 2022 - 4 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Foodtech company, Wilk, creates first cultured milk fat, cell-based yogurt

Israeli company, Wilk, has today (November 16) announced the successful development of the world’s first yogurt developed with cell-cultured milk fat. The company is a developer of cell-cultured human and animal milk and milk components and this hybrid product has been validated by external laboratories, which Wilk says confirms it meets the necessary chemical and […]

November 16, 2022 - 2 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Bio-Rad introduces pioneer antibody discovery platform for therapeutic development

Bio-Rad Laboratories Inc. yesterday (November 15) announced the launch of its Pioneer Platform, a new antibody discovery service specifically designed to develop biologic candidates. The Pioneer Platform features a phage display library engineered to include more than 200 billion unique sequences and capable of identifying high-affinity antibody candidates using Bio-Rad’s newly developed SpyDisplay selection technology. […]

November 16, 2022 - 2 minutesmins - By Liza Laws

News and Trends 16 Nov 2022

Ascletis’ monkeypox tablet receives IND approval from the FDA

A drug to treat monkeypox from Ascletis Pharma has had its investigational new drug (IND) application approved by the U.S Food and Drug Administration (FDA). The FDA made its decision based on the available data, which was 800 mg ASC10 taken twice a day, and Ascletis can now go ahead with a phase 1b clinical […]

November 16, 2022 - 3 minutesmins - By Liza Laws

Resources

Categories

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The biggest private biotech investments in August 2024

Long non-coding RNAs: what’s behind the growing “dark genome” buzz?

Grab your free report on 3D organoids and explore their future potential

Six biotech companies that could revolutionize obesity treatments

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Liza Laws

Articles by Liza Laws

Novavax’ COVID-19 vaccine gets expanded authorization for booster in adults

Sanofi’s Enjaymo for hemolytic anemia given marketing authorization by EC

MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma

NW Bio reports positive top-line results from phase 3 glioblastoma trial

AstraZeneca and Daiichi Sankyo’s Enhertu recommended for approval

Ascletis announces IND approval for treatment of advanced solid tumors

Startup Cradle raises $5.4M to design protein machines and cell factories with AI

Discovery Park celebrates 10 years and plans to double jobs over the next decade

Mineralys has positive topline results from trial evaluating treatment of hypertension

Foodtech company, Wilk, creates first cultured milk fat, cell-based yogurt

Bio-Rad introduces pioneer antibody discovery platform for therapeutic development

Ascletis’ monkeypox tablet receives IND approval from the FDA

Subscribe to our newsletter to get the latest biotech news!